FDA warns Germaphobix that its unapproved HIV dried blood spot self-collection kit is adulterated and misbranded.
What happened
FDA reviewed Germaphobix's website in January 2026 and the firm's responses to earlier FDA letters. FDA found the firm offers an HIV dried blood spot card self-collection kit to individuals for sample collection and shipment to laboratories for HIV testing without FDA marketing authorization. FDA also said the kit is not a laboratory-developed test, contrary to the firm's April 2025 response.
What FDA found
The firm offers the HIV DBS card self-collection kit for sale without an approved premarket approval application or investigational device exemption.
FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B); section 515(a), 21 U.S.C. 360e(a); section 520(g), 21 U.S.C. 360j(g)The firm did not provide FDA the required 510(k) premarket notification before introducing the device into commercial distribution.
FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)
What FDA wants
FDA asks the firm to immediately stop any activities that cause the kit to be misbranded or adulterated. Within 15 working days, the firm must write to FDA with the steps taken to correct the violations, prevent recurrence, and include documentation; if corrections are not complete, it must explain why and give a completion date.
Who should pay attention
- companies selling at-home sample collection kits
- IVD firms relying on LDT status
- labs that test self-collected dried blood spots
This is a summary. Read the original letter on fda.gov.